License upon Termination. Upon any termination of this Agreement pursuant to Sections 10.3, ALNYLAM shall enter into an agreement containing substantially the same provisions as this Agreement with any Sublicensees of QUARK existing at the time of such termination, covering the RNAi Products that had been licensed to such Sublicensee by QUARK, provided that at the time of any termination of this Agreement, such Sublicensees are in full compliance with the terms and conditions of the sublicense agreement. ALNYLAM acknowledges that such Sublicensees of QUARK that are then in full compliance with the terms and conditions of their respective sublicense agreement are third party beneficiaries of this Agreement, including this Section 9.6.
Appears in 4 contracts
Samples: License Agreement (Quark Pharmaceuticals Inc), License Agreement (Quark Pharmaceuticals Inc), License Agreement (Quark Biotech Inc)
License upon Termination. Upon any termination of this Agreement pursuant to Sections 10.39.3, ALNYLAM shall enter into an agreement containing substantially the same provisions as this Agreement with any Sublicensees of QUARK existing at the time of such termination, covering the RNAi Products that had been licensed to such Sublicensee by QUARK, provided that at the time of any termination of this Agreement, such Sublicensees are in full compliance with the terms and conditions of the sublicense agreement. ALNYLAM acknowledges that such Sublicensees of QUARK that are then in full compliance with the terms and conditions of their respective sublicense agreement are third party beneficiaries of this Agreement, including this Section 9.6.
Appears in 4 contracts
Samples: License Agreement (Quark Pharmaceuticals Inc), License Agreement (Quark Pharmaceuticals Inc), License Agreement (Quark Biotech Inc)